The FDA has issued draft guidance intended to help institutional review boards, clinical trial sponsors and researchers assess investigator qualifications, decide whether research sites are adequate, and determine whether an investigational new-drug application or investigational device exemption is necessary to protect human subjects. The guidance is up for comment through Jan. 22.